Detalhe da pesquisa
1.
Dengue Endemicity, Force of Infection, and Variation in Transmission Intensity in 13 Endemic Countries.
J Infect Dis
; 225(1): 75-83, 2022 01 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32211772
2.
Analysis of Hospitalized and Severe Dengue Cases Over the 6 years of Follow-up of the Tetravalent Dengue Vaccine (CYD-TDV) Efficacy Trials in Asia and Latin America.
Clin Infect Dis
; 73(6): 1003-1012, 2021 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33822015
3.
Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy.
N Engl J Med
; 379(4): 327-340, 2018 Jul 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-29897841
4.
Viral genetic diversity and protective efficacy of a tetravalent dengue vaccine in two phase 3 trials.
Proc Natl Acad Sci U S A
; 115(36): E8378-E8387, 2018 09 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30127007
5.
Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease.
N Engl J Med
; 373(13): 1195-206, 2015 Sep 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-26214039
6.
Corrigendum to: Dengue Endemicity, Force of Infection and Variation in Transmission Intensity From 13 Endemic Countries.
J Infect Dis
; 222(2): 341-342, 2020 06 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-32421172
7.
Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial.
Lancet
; 384(9951): 1358-65, 2014 Oct 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-25018116
8.
Immunogenicity and Safety of a Quadrivalent Meningococcal Tetanus Toxoid-Conjugate Vaccine (MenACYW-TT) in Meningococcal Vaccine-Naïve Participants across a Broad Age Range (2-55 Years) in Japan: a Phase III Randomized Study.
Jpn J Infect Dis
; 76(3): 174-182, 2023 May 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-36724939
9.
Associations of human leukocyte antigen with neutralizing antibody titers in a tetravalent dengue vaccine phase 2 efficacy trial in Thailand.
Hum Immunol
; 83(1): 53-60, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34635391
10.
Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized phase II, placebo-controlled trial.
Hum Vaccin Immunother
; 17(7): 2107-2116, 2021 07 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33626291
11.
Efficacy after 1 and 2 doses of CYD-TDV in dengue endemic areas by dengue serostatus.
Vaccine
; 38(41): 6472-6477, 2020 09 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-32773243
12.
Assessment of the long-term efficacy of a dengue vaccine against symptomatic, virologically-confirmed dengue disease by baseline dengue serostatus.
Vaccine
; 38(19): 3531-3536, 2020 04 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-32204943
13.
Bridging Efficacy of a Tetravalent Dengue Vaccine from Children/Adolescents to Adults in Highly Endemic Countries Based on Neutralizing Antibody Response.
Am J Trop Med Hyg
; 101(1): 164-179, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31115304
14.
Periods of high dengue transmission defined by rainfall do not impact efficacy of dengue vaccine in regions of endemic disease.
PLoS One
; 13(12): e0207878, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30543657
15.
Dengue seroprevalence: data from the clinical development of a tetravalent dengue vaccine in 14 countries (2005-2014).
Trans R Soc Trop Med Hyg
; 112(4): 158-168, 2018 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29800279
16.
Resource Use and Costs of Dengue: Analysis of Data from Phase III Efficacy Studies of a Tetravalent Dengue Vaccine.
Am J Trop Med Hyg
; 97(6): 1898-1903, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-29141713
17.
Symptomatic Dengue Disease in Five Southeast Asian Countries: Epidemiological Evidence from a Dengue Vaccine Trial.
PLoS Negl Trop Dis
; 10(8): e0004918, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27532617